TrovaGene Stock Price - TROV

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last: $ 0.91 ▼ -0.16 (-14.95%)
Company Name Stock Ticker Symbol Market Type
TrovaGene Inc TROV NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.06 5.94% 1.07 1.1544 0.97 1.00 1.01 19:09:16
Bid Price Ask Price Spread Spread % News
0.97 1.29 0.32 24.81% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
475 128,461 $ 1.04 $ 134,172 437,285 0.4227 - 9.6225
Last Trade Time Type Quantity Stock Price Currency
17:06:07 9 $ 0.97 USD

TrovaGene Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 6.62M 6.18M $ -16.46M -12.56 - 4.59M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

TrovaGene News

Loading Messages....

Latest TROV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TROV Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week1.291.30.881.0895189k-0.22-17.05%
1 Month1.92.080.881.4656570k-0.83-43.68%
3 Months2.013.120.882.0385469k-0.94-46.77%
6 Months3.724.72010.882.5606344k-2.65-71.24%
1 Year0.889.62250.42272.6114696k0.1921.59%
3 Years49.251.60.42275.6486871k-48.13-97.83%
5 Years48.12162.960.422722.8731692k-47.05-97.78%

TrovaGene Description

TrovaGene Inc is a clinical-stage oncology therapeutics company, developingonvansertib, a first-in-class, 3rd generation, oral and highly-selectivePolo-like Kinase 1 (PLK1) inhibitor to treat patients with leukemia,lymphoma and solid tumor cancers. The company is making advancements in its clinical development program, with three ongoingclinical trials: a Phase 1b/2 trial in Acute Myeloid Leukemia (AML); aPhase 2 trial in metastatic Castration-Resistant Prostate Cancer (mCRPC)and a Phase 1b/2 trial in metastatic Colorectal Cancer (mCRC).

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.